22:33:43 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


2024-03-13 Årsstämma 2024
2024-01-30 Bokslutskommuniké 2023
2023-10-24 Kvartalsrapport 2023-Q3
2023-07-25 Kvartalsrapport 2023-Q2
2023-04-25 Kvartalsrapport 2023-Q1
2023-03-10 Årsstämma 2023
2023-01-31 Bokslutskommuniké 2022
2022-10-25 Kvartalsrapport 2022-Q3
2022-07-21 Kvartalsrapport 2022-Q2
2022-04-26 Kvartalsrapport 2022-Q1
2022-03-09 Ordinarie utdelning OSSR 0.00 DKK
2022-03-08 Årsstämma 2022
2022-02-01 Bokslutskommuniké 2021
2021-10-26 Kvartalsrapport 2021-Q3
2021-07-22 Kvartalsrapport 2021-Q2
2021-04-27 Kvartalsrapport 2021-Q1
2021-03-09 Ordinarie utdelning OSSR 0.00 DKK
2021-03-08 Årsstämma 2021
2021-02-02 Bokslutskommuniké 2020
2020-10-27 Kvartalsrapport 2020-Q3
2020-07-23 Kvartalsrapport 2020-Q2
2020-04-30 Kvartalsrapport 2020-Q1
2020-03-13 Ordinarie utdelning OSSR 0.15 DKK
2020-03-12 Årsstämma 2020
2020-02-04 Bokslutskommuniké 2019
2019-10-22 Kvartalsrapport 2019-Q3
2019-07-25 Kvartalsrapport 2019-Q2
2019-04-30 Kvartalsrapport 2019-Q1
2019-03-08 Ordinarie utdelning OSSR 0.14 DKK
2019-03-07 Årsstämma 2019
2019-02-05 Bokslutskommuniké 2018
2018-10-24 Kvartalsrapport 2018-Q3
2018-07-25 Kvartalsrapport 2018-Q2
2018-04-25 Kvartalsrapport 2018-Q1
2018-03-09 Ordinarie utdelning OSSR 0.13 DKK
2018-03-08 Årsstämma 2018
2018-02-05 Bokslutskommuniké 2017
2017-10-24 Kvartalsrapport 2017-Q3
2017-07-25 Kvartalsrapport 2017-Q2
2017-04-27 Kvartalsrapport 2017-Q1
2017-03-10 Ordinarie utdelning OSSR 0.12 DKK
2016-03-11 Ordinarie utdelning OSSR 0.12 DKK
2016-03-10 Årsstämma 2016
2016-02-02 Bokslutskommuniké 2015
2015-10-22 Kvartalsrapport 2015-Q3
2015-07-23 Kvartalsrapport 2015-Q2
2015-04-29 Kvartalsrapport 2015-Q1
2015-03-12 Årsstämma 2015
2015-02-05 Bokslutskommuniké 2014
2014-10-24 Analytiker möte 2014


ListaLarge Cap Copenhagen
Össur hf. är ett isländskt bolag verksamma inom hälsa - och sjukvård. Idag innehas affärsinriktning mot utvecklandet av benproteser, artros samt relaterad skadehantering. Produkterna är anpassade för olika åldrar och förutsättningar beroende på patientens svårighetsgrad. Verksamheten är etablerad globalt med störst marknad inom Europa följt av Nordamerika. Huvudkontoret ligger i Reykjavik.
2022-10-07 16:50:00

Announcement no. 57/2022

7 October 2022

Össur hf. has decided to initiate a new share buyback program (the "Program") on Monday, 10 October 2022, which will replace the share buyback program that was completed yesterday, 6 October 2022. The Program will be carried out in accordance with Regulation No. 596/2014 of the European Parliament and of the Council on market abuse ("MAR"), and the Commission's delegated regulation 2016/1052. The purpose of the Program is to reduce the Company's share capital and adjust the capital structure by distributing capital to shareholders in line with the Company's Capital Structure and Capital Allocation Policy. The Company may purchase up to 2,000,000 shares under the Program, corresponding to 0.47% of the current share capital. The total consideration for shares purchased under the Program shall not exceed USD 10 million. The daily purchase shall not exceed 25% of the average volume in the 20 trading days before the purchase on the regulated market where the transaction is carried out. The purchase price shall not be higher than the price of the last independent trade or the highest current independent bid, whichever is higher, on the regulated market where the transaction is carried out. The Program will be managed by Nordea, which shall make its trading decisions independently and without influence by the Company with regards to the timing of the purchases. The Company's purchases under the Program shall be disclosed in accordance with laws and regulations. The Program will end no later than 30 September 2023, but the Company is entitled to discontinue the Program at any time. The Program has been initiated according to an authorization granted by the Annual General Meeting on 8 March 2022 to initiate share buyback programs.

The Company also reserves the right to buy back shares in block trades outside the Program with the aim of maintaining a healthy balance sheet with a target range of 2.0 - 3.0x NIBD/EBITDA. Such transactions will only be made outside "black-out periods", i.e., not within 30 days prior to publication of the Company's quarterly financial results, and when no insider information is available. Such transactions will be announced immediately after they have been carried out.

According to an authorization granted by the Annual General Meeting on 8 March 2022, the Company can purchase own shares of up to 10% of the Company's share capital as it is each time. The authorization states that the purchase price shall not be higher than the price of the last independent trade or the highest current independent bid, whichever is higher, on the regulated market where the transaction is carried out. The authorization is valid until 8 September 2024.

Further information

Edda Lára Lúðvígsdóttir, Investor Relations Director, eludvigsdottir@ossur.com,+354 844 4759

Össur press releases by e-mail

If you wish to receive Össur press releases by e-mail, please register at http://www.ossur.com/investors

About Össur

Össur (Nasdaq Copenhagen: OSSR) is a global leader in non-invasive orthopaedics that helps people live a Life Without Limitations. A recognized "Technology Pioneer" with a rich 50-year history, Össur focuses on improving people's mobility through the delivery of innovative technologies in Prosthetics and Bracing & Supports. Significant investment in research and development have led to over 2,000 patents, award-winning designs, successful clinical outcomes, and consistently strong market positions. Össur is signatory to the UN Global Compact, UN Women's Empowerment Principles, contributes to the UN Sustainable Development Goals and became Carbon Neutral in 2021. Össur operates globally and employs around 4,000 employees. www.ossur.com